The caveats should be acknowledged: Yes, all cancer centers are different. If you've seen one, you've seen one. Yes, every center director has a different political and economic situation on his or her hands, and, sure, the observation that follows in the next paragraph could well be a fluke:
Eli Lilly and Co. said FDA has granted Priority Review designation for its New Drug Application for Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor.
Boehringer Ingelheim said the supplemental New Drug Application for Gilotrif (afatinib) has been accepted for filing and granted Priority Review by FDA. The application for Gilotrif is currently under review for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 21 (L861Q), G719X, or S768I substitution mutations as detected by an FDA-approved test.
Janssen Biotech Inc. said it has submitted a New Drug Application to the FDA for apalutamide, an investigational, next generation oral androgen receptor inhibitor for men with non-metastatic castration-resistant prostate cancer. Currently, there are no FDA approved treatments for patients with non-metastatic CRPC.
FDA has cleared the first seven tesla (7T) magnetic resonance imaging device, more than doubling the static magnetic field strength available for use in the U.S.
Carl JuneSens. Roy BluntBob CaseyThe 2017 AACI Distinguished Scientist Award will be presented to Carl June.
NCCN announced the release of the Radiation Therapy Compendium that includes information designed to support clinical decision-making around the use of radiation therapy in patients with cancer.
The Lung Cancer Research Foundation and Free to Breathe announced a merger to make an even greater impact on closing the funding gap for lung cancer research. The New York State Attorney General approved the required merger documentation on Sept. 30.
A five-year, $2.4 million grant (R01CA218068) from the NCI awarded to Rutgers Cancer Institute of New Jersey behavioral scientist Jerod Stapleton, will support the development and testing of a novel behavioral intervention delivered through the social media site Facebook to reduce high-risk indoor tanning behaviors among young women.
The FDA said it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country.
